JP2019523214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019523214A5 JP2019523214A5 JP2018557405A JP2018557405A JP2019523214A5 JP 2019523214 A5 JP2019523214 A5 JP 2019523214A5 JP 2018557405 A JP2018557405 A JP 2018557405A JP 2018557405 A JP2018557405 A JP 2018557405A JP 2019523214 A5 JP2019523214 A5 JP 2019523214A5
- Authority
- JP
- Japan
- Prior art keywords
- ala
- drug conjugate
- iii
- edfyd
- bt17bdc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-trimethylbenzene Chemical group CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims 1
- 244000191761 Sida cordifolia Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1607827.1A GB201607827D0 (en) | 2016-05-04 | 2016-05-04 | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| GB1607827.1 | 2016-05-04 | ||
| PCT/GB2017/051250 WO2017191460A1 (en) | 2016-05-04 | 2017-05-04 | Bicyclic peptide-toxin conjugates specific for mt1-mmp |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019523214A JP2019523214A (ja) | 2019-08-22 |
| JP2019523214A5 true JP2019523214A5 (enExample) | 2020-06-18 |
| JP6942147B2 JP6942147B2 (ja) | 2021-09-29 |
Family
ID=56234400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557405A Active JP6942147B2 (ja) | 2016-05-04 | 2017-05-04 | Ｍｔ１−ｍｍｐに対して特異的な二環式ペプチド−毒素コンジュゲート |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10994019B2 (enExample) |
| EP (1) | EP3452096B1 (enExample) |
| JP (1) | JP6942147B2 (enExample) |
| CN (1) | CN109414510B (enExample) |
| DK (1) | DK3452096T3 (enExample) |
| ES (1) | ES3010545T3 (enExample) |
| GB (1) | GB201607827D0 (enExample) |
| WO (1) | WO2017191460A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2708459C2 (ru) | 2014-10-29 | 2019-12-09 | БайсиклРД Лимитед | Бициклические пептидные лиганды, специфичные для мт1-ммр |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) * | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| NZ756012A (en) | 2017-01-17 | 2025-10-31 | Michael David Forrest | Therapeutic inhibitors of the reverse mode of atp synthase |
| SI3592393T1 (sl) | 2017-03-10 | 2022-04-29 | Quiapeg Pharmaceuticals Ab | Sprostljivi konjugati |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| WO2019012149A1 (en) | 2017-07-13 | 2019-01-17 | Forrest Michael David | THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| EP3668550A1 (en) * | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) * | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) * | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| TW202003044A (zh) | 2018-03-09 | 2020-01-16 | 瑞典商奎亞培格製藥公司 | 可釋放之抗體結合物 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201810320D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to CD38 |
| GB201810329D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
| GB201810327D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to IL-17 |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| AU2019340472A1 (en) | 2018-09-12 | 2021-04-01 | Quiapeg Pharmaceuticals Ab | Releasable GLP-1 conjugates |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| SG11202106081YA (en) * | 2018-12-13 | 2021-07-29 | Bicycletx Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897850A1 (en) * | 2018-12-21 | 2021-10-27 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) * | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| GB201900526D0 (en) * | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for caix |
| CA3137095A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
| TWI869398B (zh) | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| CN112048013B (zh) * | 2019-06-05 | 2021-11-05 | 深圳先进技术研究院 | 靶向脑胶质瘤的多肽化合物及其合成方法与应用 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| EP4464721B1 (en) | 2019-10-03 | 2025-06-11 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| US20250186539A2 (en) | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| CA3206148A1 (en) | 2021-01-24 | 2022-07-28 | Michael David FORREST | Therapeutic modifiers of the reverse mode of atp synthase |
| GB202114282D0 (en) | 2021-10-06 | 2021-11-17 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| CN118103388A (zh) * | 2021-10-14 | 2024-05-28 | 西藏海思科制药有限公司 | EphA2的双环肽配体及其缀合物 |
| WO2023088236A1 (zh) * | 2021-11-16 | 2023-05-25 | 海思科医药集团股份有限公司 | Mt1-mmp的双环肽配体及其缀合物 |
| GB202214528D0 (en) | 2022-10-03 | 2022-11-16 | Owlstone Med Ltd | A compound |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2361739T3 (es) * | 2002-08-16 | 2011-06-21 | Immunogen, Inc. | Reticulantes con elevada reactividad y solubilidad y su uso en la preparación de conjugados para el suministro dirigido de fármacos de molécula pequeña. |
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| JPWO2004089419A1 (ja) * | 2003-04-04 | 2006-07-06 | 国立大学法人 東京大学 | 抗ｍｔ−ｍｍｐモノクローナル抗体含有脂質膜構造体 |
| EP1844337B1 (en) | 2005-01-24 | 2013-07-03 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
| JP2013518558A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 構造化されたペプチドプロセシング |
| CN103906865B (zh) * | 2011-10-07 | 2017-12-08 | 拜斯科医疗有限公司 | 结构化多肽特异性的调控 |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
| CN105683211B (zh) | 2013-10-28 | 2020-10-20 | 拜斯科阿迪有限公司 | 新型多肽 |
| RU2708459C2 (ru) * | 2014-10-29 | 2019-12-09 | БайсиклРД Лимитед | Бициклические пептидные лиганды, специфичные для мт1-ммр |
| GB201600911D0 (en) * | 2016-01-18 | 2016-03-02 | Bicycle Therapeutics Ltd | Stabilized peptide derivatives |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
| JP7387440B2 (ja) | 2016-12-23 | 2023-11-28 | バイスクルテクス・リミテッド | Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| SG11202009773VA (en) | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| US20200129630A1 (en) | 2018-10-30 | 2020-04-30 | Bicyclerd Limited | Methods for treating cancer |
-
2016
- 2016-05-04 GB GBGB1607827.1A patent/GB201607827D0/en not_active Ceased
-
2017
- 2017-05-04 ES ES17723745T patent/ES3010545T3/es active Active
- 2017-05-04 DK DK17723745.0T patent/DK3452096T3/da active
- 2017-05-04 JP JP2018557405A patent/JP6942147B2/ja active Active
- 2017-05-04 WO PCT/GB2017/051250 patent/WO2017191460A1/en not_active Ceased
- 2017-05-04 EP EP17723745.0A patent/EP3452096B1/en active Active
- 2017-05-04 CN CN201780031804.XA patent/CN109414510B/zh active Active
- 2017-05-04 US US16/097,305 patent/US10994019B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019523214A5 (enExample) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| CN113767106A (zh) | 氧杂氮杂喹唑啉-7(8h)-酮类化合物,其制法与医药上的用途 | |
| WO2015097621A3 (en) | Pharmaceutical combinations | |
| FI3430027T3 (fi) | Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa | |
| JP2013166763A5 (enExample) | ||
| EP4335511A3 (en) | Small molecule trail gene induction by normal and tumor cells as an anticancer therapy | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| MA33590B1 (fr) | Utilisation d'activateurs du récepteur nicotinique de l'acétylcholine alpha7 | |
| JP2009505676A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| EP4406606A3 (de) | Binder-wirkstoff-konjugate (adcs) und binder-prodrug-konjugate (apdcs) mit enzymatisch spaltbaren g | |
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| CL2009000200A1 (es) | Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune. | |
| CY1108885T1 (el) | Συνδυασμοι περιλαμβανοντες αντιμουσκαρινους παραγοντες και κορτικοστεροειδη | |
| JP2016536361A5 (enExample) | ||
| JP2016505010A5 (enExample) | ||
| WO2009108730A3 (en) | Forms of rifaximin and uses thereof | |
| BR112013009117A2 (pt) | sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo. | |
| JP2016525097A5 (enExample) | ||
| JP2012512158A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2006517944A5 (enExample) | ||
| EA201000039A1 (ru) | Фармацевтическая композиция, включающая солифенацин или его фармацевтически приемлемую соль | |
| JP2014534269A5 (enExample) |